AAAAAA
Results: 1-25/31
Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine
Authors:
Smale, S
Tibble, J
Sigthorsson, G
Bjarnason, I
Citation: S. Smale et al., Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine, BEST PR RES, 15(5), 2001, pp. 723-738
Authors:
Tibbe, JA
Bjarnason, I
Citation: Ja. Tibbe et I. Bjarnason, Non-invasive investigation of inflammatory bowel disease, WORLD J GAS, 7(4), 2001, pp. 460-465
Authors:
Bjarnason, I
Sherwood, R
Citation: I. Bjarnason et R. Sherwood, Fecal calprotectin: A significant step in the noninvasive assessment of intestinal inflammation, J PED GASTR, 33(1), 2001, pp. 11-13
Authors:
Jacob, M
Bjarnason, I
Rafi, S
Wrigglesworth, J
Simpson, RJ
Citation: M. Jacob et al., A study of the effects of indometacin on liver mitochondria from rats, mice and humans, ALIM PHARM, 15(11), 2001, pp. 1837-1842
Authors:
Jacob, M
Bjarnason, I
Simpson, RJ
Citation: M. Jacob et al., Effects of indomethacin on energy metabolism in rat and human jejunal tissue in vitro, CLIN SCI, 101(5), 2001, pp. 493-498
Authors:
Bjarnason, I
Rainsford, KD
Citation: I. Bjarnason et Kd. Rainsford, Are cyclooxygenase 2 inhibitors free of gastrointestinal side effects?, WEST J MED, 175(4), 2001, pp. 267-268
Authors:
Tibble, JA
Bjarnason, I
Citation: Ja. Tibble et I. Bjarnason, Fecal calprotectin as an index of intestinal inflammation, DRUGS TODAY, 37(2), 2001, pp. 85-96
Authors:
Tibble, J
Sigthorsson, G
Foster, R
Sherwood, R
Fagerhol, M
Bjarnason, I
Citation: J. Tibble et al., Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma, GUT, 49(3), 2001, pp. 402-408
Authors:
Bjarnason, I
Rainsford, KD
Citation: I. Bjarnason et Kd. Rainsford, COX-2 inhibitors and the gastrointestinal tract, GUT, 48(4), 2001, pp. 451-451
Authors:
Shah, AA
Thjodleifsson, B
Murray, FE
Kay, E
Barry, M
Sigthorsson, G
Gudjonsson, H
Oddsson, E
Price, AB
Fitzgerald, DJ
Bjarnason, I
Citation: Aa. Shah et al., Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen, GUT, 48(3), 2001, pp. 339-346
Authors:
Smale, S
Natt, RS
Orchard, TR
Russell, AS
Bjarnason, I
Citation: S. Smale et al., Inflammatory bowel disease and spondylarthropathy, ARTH RHEUM, 44(12), 2001, pp. 2728-2736
Authors:
Somasundaram, S
Sigthorsson, G
Simpson, RJ
Watts, J
Jacob, M
Tavares, IA
Rafi, S
Roseth, A
Foster, R
Price, AB
Wrigglesworth, JM
Bjarnason, I
Citation: S. Somasundaram et al., Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat, ALIM PHARM, 14(5), 2000, pp. 639-650
Authors:
Borrelli, F
Welsh, NJ
Sigthorsson, G
Simpson, R
Palizban, A
Bjarnason, I
Tavares, IA
Citation: F. Borrelli et al., Gastric acid secretion in cyclooxygenase-1 deficient mice, ALIM PHARM, 14(10), 2000, pp. 1365-1370
Authors:
Smale, S
Tibble, J
Bjarnason, I
Citation: S. Smale et al., Small intestinal permeability, CURR OPIN G, 16(2), 2000, pp. 134-139
Authors:
Tibble, JA
Sigthorsson, G
Foster, R
Bjarnason, I
Citation: Ja. Tibble et al., Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat, SC J GASTR, 35(8), 2000, pp. 802-807
Authors:
Taylor, C
Hodgson, K
Sharpstone, D
Sigthorsson, G
Coutts, M
Sherwood, R
Menzies, I
Gazzard, B
Bjarnason, I
Citation: C. Taylor et al., The prevalence and severity of intestinal disaccharidase deficiency in human immunodeficiency virus-infected subjects, SC J GASTR, 35(6), 2000, pp. 599-606
Authors:
Tibble, J
Teahon, K
Thjodleifsson, B
Roseth, A
Sigthorsson, G
Bridger, S
Foster, R
Sherwood, R
Fagerhol, M
Bjarnason, I
Citation: J. Tibble et al., A simple method for assessing intestinal inflammation in Crohn's disease, GUT, 47(4), 2000, pp. 506-513
Authors:
Sigthorsson, G
Crane, R
Simon, T
Hoover, M
Quan, H
Bolognese, J
Bjarnason, I
Citation: G. Sigthorsson et al., COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin, GUT, 47(4), 2000, pp. 527-532
Authors:
Tibble, JA
Sigthorsson, G
Bridger, S
Fagerhol, MK
Bjarnason, I
Citation: Ja. Tibble et al., Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease, GASTROENTY, 119(1), 2000, pp. 15-22
Authors:
Tibble, JA
Forgacs, I
Bjarnason, I
Przemioslo, R
Citation: Ja. Tibble et al., The effects of a preassessment clinic on nonattendance rates for day-case colonoscopy, ENDOSCOPY, 32(12), 2000, pp. 963-965
Authors:
Thomas, P
Rihani, H
Roseth, A
Sigthorsson, G
Price, A
Nicholls, RJ
Bjarnason, I
Citation: P. Thomas et al., Assessment of ileal pouch inflammation by single-stool calprotectin assay, DIS COL REC, 43(2), 2000, pp. 214-220
Authors:
Bjarnason, I
Citation: I. Bjarnason, Metabolic bone disease in patients with inflammatory bowel disease, RHEUMATOLOG, 38(9), 1999, pp. 801-804
Authors:
Bjarnason, I
Thjodleifsson, B
Citation: I. Bjarnason et B. Thjodleifsson, Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract, RHEUMATOLOG, 38, 1999, pp. 24-32
Authors:
Bjarnason, I
Citation: I. Bjarnason, Forthcoming non-steroidal anti-inflammatory drugs: are they really devoid of side effects?, ITAL J GAST, 31, 1999, pp. S27-S36
Authors:
Grimble, GK
Bonner, AB
Preedy, VR
Bjarnason, I
Peters, TJ
Citation: Gk. Grimble et al., International Nutrition Meeting 12-14th September 1996. An overview, NUTRITION, 15(7-8), 1999, pp. 599-599